MX2022015499A - Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. - Google Patents

Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Info

Publication number
MX2022015499A
MX2022015499A MX2022015499A MX2022015499A MX2022015499A MX 2022015499 A MX2022015499 A MX 2022015499A MX 2022015499 A MX2022015499 A MX 2022015499A MX 2022015499 A MX2022015499 A MX 2022015499A MX 2022015499 A MX2022015499 A MX 2022015499A
Authority
MX
Mexico
Prior art keywords
disease
methods
ulcerative colitis
crohn
jak1 inhibitor
Prior art date
Application number
MX2022015499A
Other languages
English (en)
Inventor
Ahmad Y Sheikh
Mathew M Mulhern
Peter T Mayer
Ayman D Allian
Jayanthy Jayanth
Patrick J Marroum
Thomas B Borchardt
Roopal B Thakkar
Steven Jungerwirth
Anne M Robinson
Jose Jeffrey V Enejosa
Aileen L Pangan
Ahmed Othman
Ben Klünder
Fredrik Lars Nordstrom
De Lacerda Ana Paula Machado
Mohamed - Eslam MOHAMED
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022015499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2022015499A publication Critical patent/MX2022015499A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a métodos para tratar la enfermedad de Crohn, y en particular, a métodos para inducir la remisión clínica y/o la mejoría endoscópica de la enfermedad de Crohn, mediante un inhibidor de JAK1. En ciertas modalidades, al paciente se le administra una dosis de inducción del inhibidor de JAK1 para inducir la remisión clínica y/o la mejoría endoscópica de la enfermedad de Crohn, seguida de la administración de al menos una dosis de mantenimiento del inhibidor de JAK1 a partir de entonces. En otras modalidades, la presente divulgación se refiere a métodos para tratar la colitis ulcerosa usando un inhibidor de JAK1.
MX2022015499A 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. MX2022015499A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US201762593629P 2017-12-01 2017-12-01

Publications (1)

Publication Number Publication Date
MX2022015499A true MX2022015499A (es) 2023-01-24

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010733A MX2019010733A (es) 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2022015499A MX2022015499A (es) 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010733A MX2019010733A (es) 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Country Status (9)

Country Link
US (3) US20190046527A1 (es)
EP (1) EP3592353A1 (es)
JP (2) JP2020510016A (es)
CN (1) CN110392572A (es)
AU (2) AU2018230500B2 (es)
BR (1) BR112019018576A2 (es)
CA (1) CA3052873A1 (es)
MX (2) MX2019010733A (es)
WO (2) WO2018165581A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112019018576A2 (pt) 2017-03-09 2020-04-14 Abbvie Inc métodos de tratamento de doença de crohn e colite ulcerativa
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2020063939A1 (zh) * 2018-09-29 2020-04-02 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
EP3891151A1 (en) * 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
WO2021067465A1 (en) 2019-09-30 2021-04-08 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
CA3189037A1 (en) 2020-07-08 2022-01-13 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib, preparation method therefor, and use thereof
EP4271380A1 (en) * 2020-12-29 2023-11-08 Abbvie Inc. Extended release upadacitinib formulations
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
WO2023137440A2 (en) * 2022-01-13 2023-07-20 Abbvie Inc. Method of administering upadacitinib to avoid adverse drug interactions and effects
AU2022435654A1 (en) * 2022-01-20 2024-08-01 Renata Pharmaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
WO2024052820A1 (en) * 2022-09-09 2024-03-14 Intas Pharmaceuticals Ltd. Upadacitinib formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
CA2716642C (en) 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
RS54560B1 (en) 2008-06-10 2016-06-30 Abbvie Inc. TRICYCLIC UNITS
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
CN104370909B (zh) 2009-12-01 2018-09-11 Abbvie 公司 三环化合物
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
WO2016033308A1 (en) 2014-08-27 2016-03-03 Abbvie Inc. Topical formulation
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2017378398B2 (en) * 2016-12-14 2023-02-02 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
BR112019018576A2 (pt) * 2017-03-09 2020-04-14 Abbvie Inc métodos de tratamento de doença de crohn e colite ulcerativa

Also Published As

Publication number Publication date
US11607411B2 (en) 2023-03-21
CN110392572A (zh) 2019-10-29
TW201840318A (zh) 2018-11-16
MX2019010733A (es) 2019-11-01
EP3592353A1 (en) 2020-01-15
AU2018230500A1 (en) 2019-09-19
US20190046527A1 (en) 2019-02-14
US20210361647A1 (en) 2021-11-25
AU2024203642A1 (en) 2024-06-20
US20220233527A1 (en) 2022-07-28
AU2018230500B2 (en) 2024-03-07
JP2024009963A (ja) 2024-01-23
WO2018165581A1 (en) 2018-09-13
JP2020510016A (ja) 2020-04-02
CA3052873A1 (en) 2018-09-13
WO2022178492A1 (en) 2022-08-25
BR112019018576A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
SG10201807070YA (en) Respiratory mask with nasogastric tube path
SG10201902664RA (en) Combination therapy for treating cancer
NZ732507A (en) Improved compositions for treating muscular dystrophy
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
EA201791199A1 (ru) Способ лечения болезни альцгеймера
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX2017015896A (es) Agente anticancerigeno.
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
BR112018012237A2 (pt) conjugados oligonucleotídeos-peptídeos
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2018010096A (es) Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
RU2014120624A (ru) Способ лечения инсульта